Jan 6 (Reuters) - Denali Therapeutics Inc DNLI.O:
DENALI THERAPEUTICS ANNOUNCES TOPLINE RESULTS FOR REGIMEN G EVALUATING EIF2B AGONIST DNL343 IN THE PHASE 2/3 HEALEY ALS PLATFORM TRIAL
DENALI THERAPEUTICS INC - STUDY DID NOT MEET PRIMARY ENDPOINT OF SLOWING DISEASE PROGRESSION
DENALI THERAPEUTICS INC - DNL343 FOUND TO BE SAFE AND WELL TOLERATED
DENALI THERAPEUTICS INC - KEY SECONDARY ENDPOINTS NOT STATISTICALLY DIFFERENT AT WEEK 24
Source text: ID:nGNXbtw9Bj
Further company coverage: DNLI.O
((Reuters.Briefs@thomsonreuters.com;))